Pictet Asset Management LTD Upped Halozyme Therapeutics (HALO) Position By $1.00 Million; MORO CORPORATION (MRCR) SI Decreased By 40%

October 12, 2017 - By Dolores Ford

Pictet Asset Management Ltd increased Halozyme Therapeutics Inc (HALO) stake by 6.26% reported in 2017Q2 SEC filing. Pictet Asset Management Ltd acquired 91,199 shares as Halozyme Therapeutics Inc (HALO)’s stock rose 2.38%. The Pictet Asset Management Ltd holds 1.55 million shares with $18.27M value, up from 1.46 million last quarter. Halozyme Therapeutics Inc now has $2.51B valuation. The stock rose 3.69% or $0.63 reaching $17.72 per share. About 457,634 shares traded. Halozyme Therapeutics, Inc. (NASDAQ:HALO) has risen 44.89% since October 12, 2016 and is uptrending. It has outperformed by 28.19% the S&P500.

MORO CORPORATION (OTCMKTS:MRCR) had a decrease of 40% in short interest. MRCR’s SI was 600 shares in October as released by FINRA. Its down 40% from 1,000 shares previously. With 1,000 avg volume, 1 days are for MORO CORPORATION (OTCMKTS:MRCR)’s short sellers to cover MRCR’s short positions. It is 0.00% or $0 reaching $1.06 per share. It is down 0.00% since October 12, 2016 and is . It has underperformed by 16.70% the S&P500.

Moro Corporation is an industrial holding and multi-subsidiary construction services and products company, which specializes in acquisition and management of industrial distribution, manufacturing and services businesses serving niche markets. The company has market cap of $6.49 million. The Firm operates through two divisions: Construction Materials and Construction Contracting. It currently has negative earnings. The Company’s Construction Materials division is engaged in the fabrication of concrete reinforcing steel , sheet metal (duct work), and process piping, and the distribution of miscellaneous steel and construction accessories.

Among 8 analysts covering Halozyme Therapeutics (NASDAQ:HALO), 6 have Buy rating, 0 Sell and 2 Hold. Therefore 75% are positive. Halozyme Therapeutics had 15 analyst reports since August 11, 2015 according to SRatingsIntel. The stock of Halozyme Therapeutics, Inc. (NASDAQ:HALO) earned “Buy” rating by Piper Jaffray on Wednesday, August 9. The stock of Halozyme Therapeutics, Inc. (NASDAQ:HALO) has “Overweight” rating given on Tuesday, September 22 by Barclays Capital. The firm has “Outperform” rating by Wells Fargo given on Friday, December 4. The firm has “Market Outperform” rating given on Wednesday, March 9 by JMP Securities. The rating was maintained by Piper Jaffray on Friday, September 16 with “Overweight”. Piper Jaffray maintained Halozyme Therapeutics, Inc. (NASDAQ:HALO) rating on Thursday, September 14. Piper Jaffray has “Buy” rating and $26.0 target. The rating was maintained by Barclays Capital on Wednesday, February 24 with “Overweight”. Canaccord Genuity maintained the stock with “Buy” rating in Wednesday, July 26 report. The rating was downgraded by Citigroup on Friday, January 6 to “Neutral”. On Friday, September 15 the stock rating was maintained by Deutsche Bank with “Buy”.

Investors sentiment increased to 2.02 in Q2 2017. Its up 1.26, from 0.76 in 2017Q1. It is positive, as 16 investors sold HALO shares while 30 reduced holdings. 28 funds opened positions while 65 raised stakes. 119.22 million shares or 5.94% more from 112.53 million shares in 2017Q1 were reported. Blackrock Inc stated it has 11.60M shares or 0.01% of all its holdings. D E Shaw &, New York-based fund reported 11,054 shares. Synovus Financial Corp invested in 0.01% or 36,156 shares. Royal Bancshares Of Canada, Ontario – Canada-based fund reported 4,112 shares. Paradigm Cap Mgmt has invested 0.01% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Geode Ltd Com holds 1.16 million shares or 0.01% of its portfolio. First Light Asset Mngmt Ltd holds 416,579 shares. Cubist Systematic Strategies Ltd Liability holds 42,221 shares or 0.03% of its portfolio. Baker Bros Advisors Ltd Partnership owns 1.58M shares or 0.18% of their US portfolio. Voya Investment Mngmt accumulated 50,728 shares or 0% of the stock. Wells Fargo Com Mn invested in 347,168 shares. State Board Of Administration Of Florida Retirement System, Florida-based fund reported 91,554 shares. Northern Tru has 0.01% invested in Halozyme Therapeutics, Inc. (NASDAQ:HALO) for 1.49 million shares. Artisan Prtn Partnership holds 0.02% or 998,407 shares. 126,208 were accumulated by Alps Advisors.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.